Govt suggests imposing anti-dumping duty on a pharma API from China

The recommended duty is USD 12.91 per kg.

Published On 2021-11-30 04:30 GMT   |   Update On 2021-11-30 10:08 GMT

New Delhi: The commerce ministry has recommended imposition of anti-dumping duty on a pharma raw material - Ceftriaxone Sodium Sterile - from China to guard domestic players from cheap imports.

The commerce ministry's investigation arm Directorate General of Trade Remedies (DGTR) has recommended the duty after concluding in its probe that the API (active pharma ingredient) from China has been exported at dumped prices into India, which impacted the domestic industry.

Advertisement
"The authority recommends the imposition of the anti-dumping duty on the imports of subject goods...," the directorate has said in a notification.
Ceftriaxone Sodium Sterile is an API used in formulation for treating disease like lower respiratory tract infection, skin and skin structure infection, and surgical prophylaxis.
DGTR had conducted the probe following a complaint from Nectar Life Sciences and Sterile India about the dumping of the chemical.
"The recommended duty is USD 12.91 per kg. The finance ministry takes the final decision to impose duty," reports PTI.
In a separate notification, DGTR has said it has started a sunset review probe to review the need for continued imposition of anti-dumping duties on aluminium foil from China.
The imposition of anti-dumping duty is permissible under the World Trade Organisation (WTO) regime.
The duty is aimed at ensuring fair trading practices and creating a level-playing field for domestic producers vis-a-vis foreign producers and exporters.
Medical Dialogues team had earlier reported that the DGTR had recommended the imposition of anti-dumping duty on Vitamin C, used by pharmaceutical firms for medicine production, from China to guard domestic manufacturers from cheap imports.
Tags:    
Article Source : with agency inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News